Braf V600e clinical trials

Explore recruiting braf v600e clinical trials.

Recruiting braf v600e studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Braf V600e trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

IFCT-1904 ENCO-BRAF A Phase II study of the BRAF inhibitor Encorafenib in combination with the MEK inhibitor Binimetinib in Patients with BRAFV600E-mutant metastatic Non-small Cell Lung Cancer

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2, Single-Arm study of encorafenib plus cetuximab as rechallenge treatment of BRAF V600E-mutant metastatic colorectal cancer patients after previous therapy with BRAF inhibitors-based combinations: the RefIsh trial

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A RANDOMIZED, PHASE 2, DOUBLE-BLIND STUDY TO EVALUATE THE EFFICACY OF DOSTARLIMAB PLUS CHEMOTHERAPY VERSUS PEMBROLIZUMAB PLUS CHEMOTHERAPY IN METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER

Germany, Romania, Italy, France, Spain, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

ENCORAFENIB+CETUXIMAB BEYOND PROGRESSION IN COMBINATION WITH FOLFIRI IN PATIENTS WITH BRAF V600E MUTATED METASTATIC COLORECTAL CANCER PROGRESSING ON ENCORAFENIB + CETUXIMAB

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

FFCD 2006 – NEORAF : A MULTI-CENTRE, OPEN-LABEL, PILOT TRIAL EVALUATING THE COMBINATION ENCORAFENIB AND CETUXIMAB IN A NEOADJUVANT SETTING IN PATIENTS WITH BRAF V600E-MUTATED LOCALISED COLON OR UPPER RECTUM CANCER

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Bevacizumab plus encorafenib-cetuximab in BRAF-V600E mutated metastatic colorectal cancer, a phase II study with a safety lead-in cohort, the BRAVE trial

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Braf V600e trials by city

Braf V600e in Toronto Braf V600e in Vancouver Braf V600e in Montreal Braf V600e in Calgary Braf V600e in Edmonton Braf V600e in Ottawa Braf V600e in Winnipeg Braf V600e in Quebec City Braf V600e in Hamilton Braf V600e in Kitchener Braf V600e in London Braf V600e in Halifax Braf V600e in New York Braf V600e in Los Angeles Braf V600e in Chicago Braf V600e in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease